Cantargia AB (publ) (CANTA.ST)
Cantargia AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Lund, SN, SE. The stock last traded at $1.46, down 2.73% on the session, giving a market capitalisation of $411.6M. Its beta of 1.59 implies it has historically moved more than the broad market.
Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.
Cantargia AB (publ) is most often compared with the following Healthcare names: